Browse News
Filter News
Found 496 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer
3/18/2024
Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
2/22/2024
Amylyx Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023.
-
PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
12/1/2023
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights to RO7117997. RO7117997, is an IND-ready Equilibrative Nucleoside Transporter 1 (ENT1) inhibitor discovered in partnership with Roche using the PsychoGenics’ AI-enabled phenotypic screening platforms.
-
PsychoGenics Launches an Updated Corporate Identity and Brand
11/10/2023
PsychoGenics Inc., the leading contract research organization specializing in central nervous system focused preclinical and translational drug discovery services, is proud to unveil its refreshed corporate identity and brand.
-
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
11/8/2023
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update.
-
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant to use AI platforms to design new drugs for mental health disorders
9/5/2023
PsychoGenics Inc. and Collaborations Pharmaceuticals, Inc. are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research grant, to use their combined AI tools to design new drugs for mental health disorders.
-
Ulotaront failed to meet primary endpoints in two studies. The companies said high COVID-19 placebo effect “may have masked molecule’s therapeutic effect” and plan to discuss next steps with the FDA.
-
NeuroTrauma Sciences Appoints Kevin Pong, PhD, MBA as Chief Business Officer
7/31/2023
NeuroTrauma Sciences, LLC today announced the appointment of Kevin Pong, PhD, MBA as Chief Business Officer.
-
Bryn Pharma Announces Expansion of Leadership Team as UTULY™ Investigative Needle-Free Epinephrine Nasal Spray Prepares for Market Entry
7/25/2023
Bryn Pharma, LLC announced today that it has expanded its leadership team as the company further prepares for the market entry of UTULY™, an investigational self-administered form of epinephrine being studied for the treatment of type 1 allergic reactions, including anaphylaxis.
-
The layoffs are a result of Sumitomo’s decision announced in April to combine its seven subsidiaries into one company.
-
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
7/5/2023
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer.
-
The Swiss pharma has canceled a second mid-stage trial for its investigational schizophrenia drug ralmitaront, as the competition shows promise in the space.
-
Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder
4/26/2023
Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT 1A agonist activity, for the treatment of generalized anxiety disorder (GAD).
-
Finch Therapeutics Announces Executive Leadership Transitions
4/25/2023
Finch Therapeutics Group, Inc. announced the appointment of Matthew P. Blischak as Chief Executive Officer, effective May 16, 2023. In conjunction with the appointment of Mr. Blischak, Mark Smith, PhD, will conclude his role as Chief Executive Officer and as a member of the Company’s board of directors, effective May 15, 2023.
-
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
4/24/2023
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
-
Maplight Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
4/11/2023
MapLight Therapeutics announced the appointment of Charmaine Lykins, MBA, as chief commercial officer, effective April 3,2023.
-
Cumulus Neuroscience Expands Development Support of Novel Precision CNS Therapeutics
4/11/2023
Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, today announced the establishment of new Cumulus offices in the Boston area to support its expanding partnerships with biopharma innovators.
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
4/3/2023
Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned U.S. subsidiaries to form Sumitomo Pharma America, Inc.
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
4/3/2023
Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.